Medium-throughput hydrate screening using the Crystal 16™

Pharmaceutical Development and Technology

Volumn 16, Issue 2, 2011, Pages 102-109

  Sistla, Anand ^a   Wu, Yi ^a   Khamphavong, Penney ^a   Liu, Jia ^a  

^a PFIZER INC   (United States)

Author keywords

8 mM rule; Hydration; multiple solvent; polymorphs; temperature

Indexed keywords

ACETONITRILE; CAFFEINE; CARBAMAZEPINE; CHLOROTHIAZIDE; CIMETIDINE; INDOMETACIN; NICLOSAMIDE; THEOPHYLLINE; WATER;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SCREENING; DRUG SOLUBILITY; MEDIUM THROUGHPUT SCREENING; PRIORITY JOURNAL; X RAY POWDER DIFFRACTION;

CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; HIGH-THROUGHPUT SCREENING ASSAYS; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; SOLVENTS; TEMPERATURE; WATER;

EID: 79953038644     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450903499366     Document Type: Article

References (18)

1. Pudipeddi M, Serajuddin Abu TM. Trends in solubility of poly-morphs. J Pharm Sci 2005;94:929-939.
2. Khankari RK, Grant DJW. Pharmaceutical hydrates. Termochim Acta 1995;248:61-79.
3. Guillory JK. Generation of polymorphs, hydrates, solvates, and amorphous solids. In: Brittain HG, editor. Polymorphism in pharmaceutical solids. New York: Marcel Dekker; 1999:183-226.
4. Rodriguez-Hornedo N, Murphy D. Signifcance of controlling crystallization mechanisms and kinetics in pharmaceutical sys-tems. J Pharm Sci 1999;88:651-660. (Pubitemid 29325991)
5. Gu C, Young V Jr, Grant DJW. Polymorph screening: Infuence of solvents on the rate of solvent-mediated polymorphic transfor-mation. J Pharm Sci 2001;90:1878-1890. (Pubitemid 33062608)
6. Cui Y Yao E. Evaluation of hydrate-screening methods. J Pharm Sci 2008;97:2730-2744.
7. Wikström H, Rantnen, J, Gift AD, Taylor, LS. Toward an under-standing of the factors infuencing anhydrate-to-hydrate trans-formation kinetics in aqueous environments. Cryst Growth Des 2008;8:2684-2693.
8. Miller JM, Collman BM, Greene LR, Grant DJW, Blackburn AC Identifying the stable polymorph early in the drug discover-development process. Pharm Dev Tech 2005; 10:291-297. (Pubitemid 40677449)
9. Golles F. Examination and calculation of thermodynamic data from experimental measurements. I. Te numerical integra-tion of the vapor-pressure curves of the system methanol-water. Monatsh Chem 1961;92:981-991.
10. Golles F. Examination and calculation of thermodynamic data from experimental measurements. II. Te numerical integra-tion of the vapor-pressure curves of the system ethanol-water. Monatsh Chem 1962;93:191-220.
11. Zhu H, Yuen C, Grant DJW. Infuence of water activity in organic solvent + water mixtures on the nature of the crystallizing drug phase. 1. Teophylline. Int J Pharm 1996;135:151-160. (Pubitemid 26260884)
12. Solkolova EP, Moarachevskii AG. Liquid-vapour equilibrium in the propan-2-ol-water and propan-2-ol-benzene system. Rus J Phys Chem 1967;41:863-866.
13. Chirikova ZP, Galata LA, Kotova ZN, Kofman LS. Liquid-vapor equilibrium in the system acetonitrile-water. Rus J Phys Chem 1966;40:493-496.
14. Pirttimaki J, Laine E. Te transformation of anhydrate and hydrate forms of cafeine at 100% RH and 0% RH. Eur J Pharm Sci 1994;1:203-208. (Pubitemid 24063819)
15. van Tonder EC, Maleka TSP, Liebenberg W, Song M, Wurster DE, de Villiers MM. Preparation and physicochemical properties of niclosamide anhydrate and two monohydrates. Int J Pharm 2004;269:417-432. (Pubitemid 38045305)
16. Shibata M, Kokubo H, Morimoto K, Morisaka K, Ishida T, Inoue M. X-ray structural studies and physicochemical properties of cimetidine polymorphism. J Pharm Sci 1983; 72:1436-1442. (Pubitemid 14208320)
17. Suryanarayanan R. Determination of the relative amounts of anhydrous carbamazepine (C15H12N2O) and car-bamazepine dihydrate (C15H12N2O, 2H2O) in a mix-ture by powder X-ray difractometry. Pharm Res 1989; 6:1017-1024. (Pubitemid 20094223)
18. Ticehurst MD, Storey RA, Watt C Application of slurry bridg-ing experiments at controlled water activities to predict the solid-state conversion between anhydrous and hydrated forms using theophylline as a model drug. Int J Pharm 2002; 247:1-10. (Pubitemid 35341134)